In patient-derived GBM models, ERAS-801 showed a survival benefit of 93% in EGFR mutant and/or amplified models, significant brain penetrance, and prolonged survival compared to previously approved EGFR-tyrosine kinase inhibitors like erlotinib (Figure 1). The gene discussed is EGFR; the disease is glioblastoma.